Wall Street analysts expect Cardlytics Inc (NASDAQ:CDLX) to report earnings of ($0.47) per share for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Cardlytics’ earnings. The lowest EPS estimate is ($0.71) and the highest is ($0.36). The business is expected to issue its next quarterly earnings report on Tuesday, November 13th.

According to Zacks, analysts expect that Cardlytics will report full-year earnings of ($1.30) per share for the current fiscal year, with EPS estimates ranging from ($1.36) to ($1.24). For the next financial year, analysts forecast that the firm will report earnings of ($1.10) per share, with EPS estimates ranging from ($1.17) to ($0.98). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Cardlytics.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings results on Tuesday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.32. The business had revenue of $35.57 million for the quarter, compared to the consensus estimate of $34.89 million. The firm’s quarterly revenue was up 8.4% compared to the same quarter last year.

A number of research analysts have recently issued reports on CDLX shares. SunTrust Banks reaffirmed a “buy” rating and set a $27.00 price target on shares of Cardlytics in a report on Tuesday, September 11th. Bank of America reaffirmed a “hold” rating and set a $22.00 price target on shares of Cardlytics in a report on Friday, August 17th. Zacks Investment Research downgraded Cardlytics from a “hold” rating to a “sell” rating in a report on Tuesday, August 21st. Finally, KeyCorp lowered their price target on Cardlytics from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Wednesday, August 15th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $24.40.

Shares of NASDAQ:CDLX traded down $1.04 during midday trading on Friday, reaching $22.80. 159,365 shares of the company’s stock traded hands, compared to its average volume of 177,030. The company has a market cap of $507.41 million and a P/E ratio of -2.84. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.24 and a quick ratio of 2.24. Cardlytics has a one year low of $11.10 and a one year high of $28.29.

In other news, COO Lynne Marie Laube sold 1,349 shares of the company’s stock in a transaction on Friday, August 17th. The stock was sold at an average price of $20.66, for a total transaction of $27,870.34. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Scott D. Grimes sold 1,445 shares of the company’s stock in a transaction on Friday, August 17th. The shares were sold at an average price of $20.66, for a total value of $29,853.70. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 155,194 shares of company stock worth $3,863,308.

A number of institutional investors have recently bought and sold shares of CDLX. FMR LLC increased its position in Cardlytics by 32.1% during the second quarter. FMR LLC now owns 1,894,196 shares of the company’s stock valued at $41,218,000 after acquiring an additional 459,831 shares during the last quarter. Federated Investors Inc. PA purchased a new stake in Cardlytics during the first quarter valued at $5,852,000. BlackRock Inc. purchased a new stake in Cardlytics during the first quarter valued at $3,420,000. Frontier Capital Management Co. LLC increased its position in Cardlytics by 2,150.0% during the second quarter. Frontier Capital Management Co. LLC now owns 227,585 shares of the company’s stock valued at $4,952,000 after acquiring an additional 217,470 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in Cardlytics during the first quarter valued at $2,588,000. Institutional investors own 49.66% of the company’s stock.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

See Also: Growth Stocks

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.